Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology
Analysis of the individual radiosensitivity in pediatric oncology
| Condition(s) | Radiosensitivity, Pediatric Cancer, Radiation Toxicity |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Analysis of the individual radiosensitivity in pediatric oncology |
| Who can participate | Inclusion Criteria: * Minor patient treated for a brain tumor, Ewing tumor, malignant mesenchymal tumor, neuroblastoma, nephroblastoma, Hodgkin's lymphoma treated with radiotherapy (+/- chemotherapy) for curative purposes. * Children or adolescents \> 3 years old and \< 18 years old * Patient with an indication for radiotherapy as part of the primary tumor local control strategy * Theoretical indication for radiotherapy in standard fractionation (1.8 Gy to 2.2 Gy / fraction: 5 fr/week) whatever the technique and the particle used * Patient affiliated with a social security scheme * Patient and/or parents or holders of parental authority having dated and signed an informed consent Exclusion criteria: * Patients with contraindications to blood sampling * Patients with contraindications to ra |
| Ages | 3 Years to 18 Years |
| Sex | All |
| Lead sponsor | Neolys |
| Locations | Caen, France; Lille, France |
| Start date | 2023-12-02 |
| NCT ID | NCT06033183 |
| Official listing | https://clinicaltrials.gov/study/NCT06033183 |